文献速递神经肿瘤

静默型促肾上腺皮质激素垂体腺瘤:临床特征、长期结局与复发管理

Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence.
PubMed 文献 · J Neurosurg · 2021-05-07

该单中心回顾性研究比较了2000至2019年手术治疗的100例静默型促肾上腺皮质激素垂体腺瘤(SCA)与841例其他亚型无功能垂体腺瘤(NFA)。SCA组更年轻、女性更多,颅神经病变与头痛更常见,Ki-67更高,无进展生存期明显更短(24.5 vs 51.1个月,p=0.0011),提示其生物学行为更具侵袭性。

要点

  • SCA较标准NFA更年轻、女性比例更高,颅神经病变和头痛更常见。
  • SCA的Ki-67显著更高,无进展生存期约为其他NFA的一半。
  • SCA术后需密切影像与临床随访,残留病灶可考虑早期辅助放疗。

核心结论

  • SCA比标准NFA生物学上更具侵袭性,无进展生存期仅约为其他NFA的一半。
  • 建议对SCA患者密切进行神经影像和临床随访,残留病灶尤其年轻患者可考虑早期术后辅助放疗。

研究设计与样本

  • 单中心回顾性分析,纳入2000至2019年手术治疗的100例SCA和841例其他亚型NFA患者。
  • 比较两组人口学、肿瘤特征、手术与影像数据、内分泌及神经结局。

主要发现

  • SCA组颅神经病变13% vs 5.7%(p=0.0051),头痛53% vs 42.3%(p=0.042)。
  • SCA组女性60% vs 45.8%(p=0.0071),年龄50.5±13.3 vs 54.6±14.9岁(p=0.0082)。
  • SCA组Ki-67为2.88±2.79,NFA组为1.94±1.99(p=0.015)。
  • SCA组无进展生存期24.5个月 vs NFA组51.1个月(p=0.0011)。
  • SCA进展队列中放疗后33%(n=4/12)仍进展,半数(n=6)未获满意肿瘤控制。

关键数值与推荐

  • 再手术率SCA 16% vs NFA 15.7%(p=0.98)。
  • 术前全垂体功能减退NFA更高:2% vs 6.1%(p=0.0033)。
  • 平均肿瘤直径SCA 24±10.8 mm vs NFA 26±11.3 mm(p=0.05)。
  • 海绵窦侵犯SCA 56% vs NFA 49.7%,未达统计学显著。
  • 切除范围、术中脑脊液漏、内分泌或神经结局及术后并发症无显著差异。

临床怎么用

  • SCA术后应加强神经影像与临床随访以早期发现进展。
  • 对残留病灶可考虑早期术后辅助放疗,尤其年轻患者。
  • 进展后需综合评估放疗与再次手术策略,因部分肿瘤控制不佳。

局限性

  • 为单中心回顾性研究,可能存在选择偏倚。
  • SCA进展队列样本量小(n=12),放疗相关结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Silent corticotroph adenomas (SCAs) are a distinct subtype of nonfunctioning pituitary adenomas (NFAs) that demonstrate positive immunohistochemistry for adrenocorticotropic hormone (ACTH) without causing Cushing's disease. SCAs are hypothesized to exhibit more aggressive behavior than standard NFAs. The authors analyzed their institution's surgical experience with SCAs in an effort to characterize rates of invasion, postoperative clinical outcomes, and patterns of disease recurrence and progression. The secondary objectives were to define the best treatment strategies in the event of tumor recurrence and progression. METHODS: A retrospective analysis of patients treated at the authors' institution identified 100 patients with SCAs and 841 patients with NFAs of other subtypes who were treated surgically from 2000 to 2019. Patient demographics, tumor characteristics, surgical and neuroimaging data, rates of endocrinopathy, and neurological outcomes were recorded. Cohorts of patients with SCAs and patients with standard NFAs were compared with regard to these characteristics and outcomes. RESULTS: The SCA cohort presented with cranial neuropathy (13% vs 5.7%, p = 0.0051) and headache (53% vs 42.3%, p = 0.042) compared to the NFA cohort, despite similar rates of apoplexy. The SCA cohort included a higher proportion of women (SCA 60% vs NFA 45.8%, p = 0.0071) and younger age at presentation (SCA 50.5 ± 13.3 vs NFA 54.6 ± 14.9 years of age, p = 0.0082). Reoperations were comparable between the cohorts (SCA 16% vs NFA 15.7%, p = 0.98). Preoperative pituitary function was comparable between the cohorts with the exception of higher rates of preoperative panhypopituitarism in NFA patients (2% vs 6.1%, respectively; p = 0.0033). The mean tumor diameter in SCA patients was 24 ± 10.8 mm compared to 26 ± 11.3 mm in NFA patients (p = 0.05). Rates of cavernous sinus invasion were higher in the SCA group (56% vs 49.7%), although this result did not reach statistical significance. There were no significant differences in extent of resection, intraoperative CSF leak rates, endocrine or neurological outcomes, or postoperative complications. Ki-67 rates were significantly increased in the SCA cohort (2.88 ± 2.79) compared to the NFA cohort (1.94 ± 1.99) (p = 0.015). Although no differences in overall rates of progression or recurrence were noted, SCAs had a significantly lower progression-free survival (24.5 vs 51.1 months, p = 0.0011). Among the SCA cohort, progression was noted despite the use of adjuvant radiosurgery in 33% (n = 4/12) of treated tumors. Adequate tumor control was not achieved in half (n = 6) of the SCA progression cohort despite radiosurgery or multiple resections. CONCLUSIONS: In this study, to the authors' knowledge the largest surgical series to assess outcomes in SCAs to date, the findings suggest that SCAs are more biologically aggressive tumors than standard NFAs. The progression-free survival duration of patients with SCAs is only about half that of patients with other NFAs. Therefore, close neuroimaging and clinical follow-up are warranted in patients with SCAs, and residual disease should be considered for early postoperative adjuvant radiosurgery, particularly in younger patients.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Strickland BA, Shahrestani S, Briggs RG, et al. Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence. J Neurosurg. 2021. PMID: 33962375. doi:10.3171/2020.10.JNS203236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。